Compare BANR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANR | NVAX |
|---|---|---|
| Founded | 1890 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.6B |
| IPO Year | 2015 | 1996 |
| Metric | BANR | NVAX |
|---|---|---|
| Price | $59.81 | $8.49 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 9 |
| Target Price | ★ $71.20 | $11.33 |
| AVG Volume (30 Days) | 299.6K | ★ 4.4M |
| Earning Date | 04-15-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.31% | N/A |
| EPS Growth | 15.57 | ★ 309.76 |
| EPS | ★ 5.64 | 2.58 |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | $0.73 | N/A |
| Revenue Next Year | $5.69 | N/A |
| P/E Ratio | $10.70 | ★ $3.47 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $54.01 | $5.01 |
| 52 Week High | $69.83 | $11.85 |
| Indicator | BANR | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 38.12 |
| Support Level | $57.78 | $8.01 |
| Resistance Level | $64.36 | $9.05 |
| Average True Range (ATR) | 1.38 | 0.54 |
| MACD | 0.26 | -0.23 |
| Stochastic Oscillator | 64.66 | 1.81 |
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.